Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multi-center, Randomized, Open-label, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Non-dialysis Chronic Kidney Disease Patients With Anemia

NCT02988973 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02988973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02988973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multi-center, Randomized, Open-label, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Non-dialysis Chronic Kidney Disease Patients With Anemia
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
January 12, 2017
Completion date
March 26, 2020
Enrollment
334 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease